Molecular mimics of SVEP1 could be used therapeutically to enhance myelopoiesis, and inhibitors of SVEP1 binding to HSPC could be used to treat myeloproliferative disorders and leukemia. This evidence concerns the gene SVEP1 and myeloproliferative disorder.